cadenas
  • Innovative Therapies
    for Children with Cancer in Europe
  • Contact us

Leukemias

  • A phase I/II study of Azacytidine (VIDAZA®) in pediatric patients with relapsed high-grade pediatric MDS or JMML

  • Phase 1b/2 Study of Carfilzomib in combination with Dexamethasone, Mitoxantrone, PEG-asparaginase, and Vincristine (R3 Induction Backbone) in pediatric subjects with relapsed or refractory Acute...

  • A Prospective, Multicentric Clinical Proof-of-Concept Study to Stratify Targeted Therapies Adapted to Molecular Profiling of Relapsed or Refractory Pediatric Tumors

  • European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors in children

  • ITCC-062 PARC

    Leukemias

    Multicentre, open label, single arm Phase II study of Pegylated recombinant human arginase (BCT-100) in children > 1 year and <18 years with solid tumours, CNS malignancies and leukemias that are...

  • A phase IB/II open label study of the MEK-inhibitor selumetinib in combination with dexamethasone for paediatric and adolescent patients with ≥2nd relapsed precursor B or T ALL

  • Ibrutinib randomized safety and efficacy study in pediatric patients with mature B-cell NHL, including Burkitt lymphoma/Leukemia and Diffuse Large B-cell Lymphoma

  • A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric Patients with Select Relapsed or Refractory Malignancies

1 - 8 sur 9
<< Premier < Précédent 1 2 Dernier >>